Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Nechushtan, Hovav ^a   Hamburger, Tamar ^a   Mendelson, Susan ^a   Kadouri, Luna ^a   Sharon, Nir ^a   Pikarsky, Eli ^a   Peretz, Tamar ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PROTEIN MDM2; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN; MDM2 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HUMAN; JEW; MENOPAUSE; ONSET AGE; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; ADULT; AGED; BREAST TUMOR; GENE FREQUENCY; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; SURVIVAL;

ADULT; AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; JEWS; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; SURVIVAL ANALYSIS;

EID: 65349179110     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-60     Document Type: Article

References (26)

1. Levav-Cohen Y Haupt S Haupt Y Mdm2 in growth signaling and cancer Growth Factors 2005, 23(3):183-192 10.1080/08977190500196218 16243710
2. Bond GL Hu W Bond EE Robins H Lutzker SG Arva NC Bargonetti J Bartel F Taubert H Wuerl P et al A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans Cell 2004, 119(5):591-602 10.1016/ j.cell.2004.11.022 15550242
3. Wilkening S Bermejo JL Burwinkel B Klaes R Bartram CR Meindl A Bugert P Schmutzler RK et al Wappenschmidt B Untch M The single nucleotide polymorphism IVS1+309 in mouse double minute 2 does not affect risk of familial breast cancer Cancer Res 2006 66 2 646 648 10.1158/ 0008-5472.CAN-05-3168 16423991
4. Yarden RI Friedman E Metsuyanim S Olender T Ben-Asher E Papa MZ MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent Breast Cancer Res Treat 2007 18026875
5. Wasielewski M Nagel JH Brekelmans C Klijn JG Ouweland van den A Meijers-Heijboer H Schutte M MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling Breast Cancer Res Treat 2007, 104(2):153-157 10.1007/s10549-006-9407-5 17080308
6. Bond GL Hirshfield KM Kirchhoff T Alexe G Bond EE Robins H Bartel F Taubert H Wuerl P Hait W et al MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner Cancer Res 2006, 66(10):5104-5110 10.1158/0008-5472.CAN-06-0180 16707433
7. Turbin DA Cheang MC Bajdik CD Gelmon KA Yorida E De Luca A Nielsen TO Huntsman DG Gilks CB MDM2 protein expression is a negative prognostic marker in breast carcinoma Mod Pathol 2006, 19(1):69-74 10.1038/ modpathol.3800484 16258514
8. Baekelandt M Kristensen GB Nesland JM Trope CG Holm R Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer J Clin Oncol 1999, 17(7):2061 10561259
9. Ranuncolo SM Varela M Morandi A Lastiri J Christiansen S Bal de Kier Joffe E Pallotta MG Puricelli L Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas J Neurooncol 2004, 68(2):113-121 10.1023/ B:NEON.0000027741.19213.99 15218947
10. Ohmiya N Taguchi A Mabuchi N Itoh A Hirooka Y Niwa Y Goto H MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis J Clin Oncol 2006, 24(27):4434-4440 10.1200/JCO.2005.04.1459 16983111
11. Hirata H Hinoda Y Kikuno N Kawamoto K Suehiro Y Tanaka Y Dahiya R MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma Clin Cancer Res 2007, 13(14):4123-4129 10.1158/ 1078-0432.CCR-07-0609 17634539
12. Mathoulin-Portier MP Viens P Cowen D Bertucci F Houvenaeghel G Geneix J Puig B Bardou VJ Jacquemier J Prognostic value of simultaneous expression of p21 and mdm2 in breast carcinomas treated by adjuvant chemotherapy with antracyclin Oncol Rep 2000, 7(3):675-680 10767389
13. Oddoux C Struewing JP Clayton CM Neuhausen S Brody LC Kaback M Haas B Norton L Borgen P Jhanwar S et al The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1% Nature genetics 1996, 14(2):188-190 10.1038/ng1096-188 8841192
14. Struewing JP Abeliovich D Peretz T Avishai N Kaback MM Collins FS Brody LC The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals Nature genetics 1995, 11(2):198-200 10.1038/ng1095-198 7550349
15. Abeliovich D Kaduri L Lerer I Weinberg N Amir G Sagi M Zlotogora J Heching N Peretz T The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women American journal of human genetics 1997, 60(3):505-514 1712523 9042909
16. Atwal GS Bond GL Metsuyanim S Papa M Friedman E Distelman-Menachem T Ben Asher E Lancet D Ross DA Sninsky J et al Haplotype structure and selection of the MDM2 oncogene in humans Proceedings of the National Academy of Sciences of the United States of America 2007, 104(11):4524-4529 1838634 17360557 10.1073/pnas.0610998104
17. Copson ER White HE Blaydes JP Robinson DO Johnson PW Eccles DM Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers BMC Cancer 2006, 6:80 1483833 16563154 10.1186/1471-2407-6-80
18. Wilkening S Bermejo JL Hemminki K MDM2 SNP309 and cancer risk: A combined analysis Carcinogenesis 2007, 28(11):2262-2267 10.1093/carcin/ bgm191 17827408
19. Kadouri L Kote-Jarai Z Hubert A Durocher F Abeliovich D Glaser B Hamburger T Eeles RA Peretz T A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers Br J Cancer 2004, 90(10):2002-2005 10.1038/ sj.bjc.6601837 15138485
20. Alazzouzi H Suriano G Guerra A Plaja A Espin E Armengol M Alhopuro P Velho S Shinomura Y Gonzalez-Aguilera JJ et al Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells J Med Genet 2007, 44(1):75-80 10.1136/jmg.2006.042572 16825434
21. Stommel JM Wahl GM Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation Embo J 2004, 23(7):1547-1556 391059 15029243 10.1038/sj.emboj.7600145
22. Stommel JM Wahl GM A new twist in the feedback loop: Stress-activated MDM2 destabilization is required for p53 activation Cell Cycle 2005, 4(3):411-417 15684615
23. Chandler DS Singh RK Caldwell LC Bitler JL Lozano G Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4 Cancer Res 2006, 66(19):9502-9508 10.1158/ 0008-5472.CAN-05-4271 17018606
24. Phan RT Dalla-Favera R The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells Nature 2004, 432(7017):635-639 10.1038/ nature03147 15577913
25. Phan RT Saito M Kitagawa Y Means AR Dalla-Favera R Genotoxic stress regulates expression of the proto-oncogene Bcl6 in germinal center B cells Nat Immunol 2007, 8(10):1132-1139 10.1038/ni1508 17828269
26. Lossos IS Jones CD Warnke R Natkunam Y Kaizer H Zehnder JL Tibshirani R Levy R Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma Blood 2001, 98(4):945-951 10.1182/blood.V98.4.945 11493437